TIL - Iovance Bio stock falls 5% on LN-145 data in non-small cell lung cancer

Iovance Biotherapeutics (IOVA) drops 5.1% premarket after announcing clinical data for its tumor infiltrating lymphocyte ((TIL)) therapy LN-145 in patients with metastatic non-small cell lung cancer (mNSCLC). The overall response rate ((ORR)) was 21.4% (n=28, one complete response and five partial responses) following one or more prior systemic therapies including immunotherapy.Disease control rate ((DCR)) was 64.3%.Median duration of response was not reached at a median study follow up of 8.2 months.Historically, ORRs of ~20% were reported with immune checkpoint inhibitor (ICIs) as second-line therapy in ICI-naïve patients who progressed on front-line chemotherapy.IOVA anticipates presenting additional Cohort 3B data at a medical meeting in H2 2021. Iovance also announced that it dosed the first patient in IOV-LUN-202 study in second-line mNSCLC.Source: Company Presentation

For further details see:

Iovance Bio stock falls 5% on LN-145 data in non-small cell lung cancer